Cantor Fitzgerald Forecasts TSHA FY2026 Earnings

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Taysha Gene Therapies in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings per share of ($0.42) for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $7.00 price target on the stock. The consensus estimate for Taysha Gene Therapies' current full-year earnings is ($0.35) per share.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The company had revenue of $2.30 million for the quarter, compared to analyst estimates of $1.48 million. During the same period last year, the company posted ($0.10) earnings per share.

Several other research analysts have also commented on TSHA. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday. Chardan Capital raised their target price on Taysha Gene Therapies from $7.00 to $9.00 and gave the company a "buy" rating in a research note on Thursday, May 29th. Canaccord Genuity Group raised their target price on Taysha Gene Therapies from $9.00 to $11.00 and gave the company a "buy" rating in a research note on Tuesday, June 3rd. JMP Securities raised their target price on Taysha Gene Therapies from $5.00 to $6.00 and gave the company a "market outperform" rating in a research note on Thursday, May 29th. Finally, Citigroup restated an "outperform" rating on shares of Taysha Gene Therapies in a research note on Thursday, May 29th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies has a consensus rating of "Buy" and a consensus target price of $7.57.

Taysha Gene Therapies Stock Down 4.2%

NASDAQ:TSHA traded down $0.11 during mid-day trading on Wednesday, hitting $2.54. The company had a trading volume of 2,460,645 shares, compared to its average volume of 3,091,477. The business has a fifty day simple moving average of $2.18 and a 200-day simple moving average of $1.93. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies has a 1 year low of $1.05 and a 1 year high of $4.07. The firm has a market capitalization of $545.24 million, a price-to-earnings ratio of 4.03 and a beta of 1.04.

Insider Buying and Selling

In other news, major shareholder Paul B. Manning purchased 750,000 shares of the firm's stock in a transaction that occurred on Friday, May 30th. The stock was acquired at an average cost of $2.75 per share, for a total transaction of $2,062,500.00. Following the completion of the purchase, the insider now owns 2,841,704 shares of the company's stock, valued at approximately $7,814,686. This trade represents a 35.86% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.78% of the company's stock.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of hedge funds and other institutional investors have recently bought and sold shares of TSHA. Ground Swell Capital LLC acquired a new position in Taysha Gene Therapies in the fourth quarter valued at approximately $25,000. Cibc World Markets Corp acquired a new position in Taysha Gene Therapies in the fourth quarter valued at approximately $28,000. E Fund Management Co. Ltd. acquired a new position in Taysha Gene Therapies in the fourth quarter valued at approximately $31,000. Hsbc Holdings PLC boosted its stake in Taysha Gene Therapies by 65.6% in the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after acquiring an additional 8,076 shares during the period. Finally, AXQ Capital LP acquired a new position in Taysha Gene Therapies in the fourth quarter valued at approximately $39,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.